Resource Logo

Vaccination against feline leukaemia using a new feline herpesvirus type 1 vector.


Vaccine. 1996 Nov;14(16):1511-6. Unique Identifier : AIDSLINE

A recombinant feline herpesvirus type 1 (FHV-1) was constructed expressing the envelope glycoprotein gene from feline leukaemia virus (FeLV). The expression cassette containing the long terminal repeat promoter from Rous sarcoma virus was stably integrated at the locus downstream of the gC homologue in FHV-1. Oronasal vaccination with recombinant FHV-1 engendered significant protection against challenge with the homologous FelV-A/Glasgow-1 isolate. Three of four vaccinated cats did not become viraemic for FeLV and developed serum neutralizing antibodies while five of six controls became persistently infected after challenge. However, latent FeLV was detected at 12 weeks after challenge in bone marrow cultures of all animals except one. The potential of this new vector to protect against FeLV was compared with previous reports using live recombinant vaccines.

*Genetic Vectors/IMMUNOLOGY *Herpesviridae/GENETICS *Leukemia Virus, Feline/IMMUNOLOGY *Leukemia, Feline/PREVENTION & CONTROL *Vaccines, Synthetic/IMMUNOLOGY *Viral Vaccines/IMMUNOLOGY


Information in this article was accurate in June 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.